Conference Description:

For drugs anywhere, it's the safety in patients which is a huge issue, constantly under surveillance, irrespective of where the drug is in its pipeline.
The Global Pharmaceutical Market currently has a market value of $1057 billion. If a drug is found to be unsafe, causing serious side effects, it can have a huge knock on effect on revenue, causing huge losses to pharmaceutical companies manufacturing the drug.

Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations.

Network and learn from:

- David Lewis, Senior Adviser Pharmacovigilance, CMO Patient Safety, Novartis
- Peter De Veene, Senior Vice President and Head Global Drug Safety and QPPV, Grunenthal
- Simon Ashworth, VP EU QPPV, EU Head Compliance and Marketed Products and Head PV Affiliate Relations, Takeda
- Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MHRA
- John Solomon, Head of Pharmacovigilance-UK And Ireland, Sanofi
- Bjarke Naver, Head of Pharmacovigilance Science, LEO Pharma
- Sue Rees, EU QPPV, Executive Director, Global Safety, Amgen
- Jackie Roberts, Executive Director Regulatory, Pharmacovigilance and Medical UK/IE/Malta and MENA, Accord Healthcare
- Philip Eichorn, Senior Director, Worldwide Safety and Regulatory, Pfizer
- Kashif Sheikh, Safety Surveillance Specialist, Novo Nordisk

FEATURED HIGHLIGHTS:

- MHRA spotlight presentation on the future of Clinical Trial Regulations
- Hear first experiences with the new Eudravigilence system
- Gain insight into how competitors are reporting adverse effects under the new legislation and system
- Discuss risk-minimisation and signal detection strategies with industry-thought leaders
- Evaluate the benefits and pitfalls of patient involvement and patient support programs

Price:
Standard (early-bird rates available): GBP 1499

Time: 8:30 am to 5:00 pm